148 related articles for article (PubMed ID: 38303234)
21. Chemoradiation and consolidation chemotherapy for rectal cancer provides a high rate of organ preservation with a very good long-term oncological outcome: a single-center cohort series.
Asoglu O; Bulut A; Aliyev V; Piozzi GN; Guven K; Bakır B; Goksel S
World J Surg Oncol; 2022 Nov; 20(1):358. PubMed ID: 36352416
[TBL] [Abstract][Full Text] [Related]
22. Practice Patterns for Organ Preservation in US Patients With Rectal Cancer, 2006-2020.
Loria A; Tejani MA; Temple LK; Justiniano CF; Melucci AD; Becerra AZ; Monson JRT; Aquina CT; Fleming FJ
JAMA Oncol; 2024 Jan; 10(1):79-86. PubMed ID: 37943566
[TBL] [Abstract][Full Text] [Related]
23. A meta-analysis of the watch-and-wait strategy versus total mesorectal excision for rectal cancer exhibiting complete clinical response after neoadjuvant chemoradiotherapy.
Yu G; Lu W; Jiao Z; Qiao J; Ma S; Liu X
World J Surg Oncol; 2021 Oct; 19(1):305. PubMed ID: 34663341
[TBL] [Abstract][Full Text] [Related]
24. Rectal Sparing Approach After Neoadjuvant Therapy in Patients with Rectal Cancer: The Preliminary Results of the ReSARCh Trial.
Marchegiani F; Palatucci V; Capelli G; Guerrieri M; Belluco C; Rega D; Morpurgo E; Coco C; Restivo A; De Franciscis S; Aschele C; Perin A; Bonomo M; Muratore A; Spinelli A; Ramuscello S; Bergamo F; Montesi G; Spolverato G; Del Bianco P; Gambacorta MA; Delrio P; Pucciarelli S
Ann Surg Oncol; 2022 Mar; 29(3):1880-1889. PubMed ID: 34855063
[TBL] [Abstract][Full Text] [Related]
25. [Principle of surgical management for rectal cancer patients with complete clinical response after neoadjuvant therapy].
Li XX; Luo DK
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):342-348. PubMed ID: 31054548
[TBL] [Abstract][Full Text] [Related]
26. [Comparison of short-term efficacy and perioperative safety between neoadjuvant therapy and total neoadjuvant therapy in patients with locally advanced rectal cancer].
Zhai ZW; Zhang KN; Wang C; Han JG; Ma HC; Wei GH; Yang Y; Wang ZJ
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):274-280. PubMed ID: 32192307
[No Abstract] [Full Text] [Related]
27. [A Case of Locally Advanced Rectal Cancer Treated Successfully with TNT].
Koizumi A; Suzuki Y; Shigehara F; Tsukamoto M; Takashima J; Yamazaki K; Sugimoto H; Fujimoto D; Miura F; Taniguchi K; Matsutani N; Kobayashi H
Gan To Kagaku Ryoho; 2022 Dec; 49(13):1640-1641. PubMed ID: 36733161
[TBL] [Abstract][Full Text] [Related]
28. [Evaluation strategy of complete response after neoadjuvant therapy for rectal cancer].
Han JG; Wang ZJ
Zhonghua Wai Ke Za Zhi; 2023 Sep; 61(9):738-743. PubMed ID: 37491164
[TBL] [Abstract][Full Text] [Related]
29. Organ preservation for rectal cancer (GRECCAR 2): a prospective, randomised, open-label, multicentre, phase 3 trial.
Rullier E; Rouanet P; Tuech JJ; Valverde A; Lelong B; Rivoire M; Faucheron JL; Jafari M; Portier G; Meunier B; Sileznieff I; Prudhomme M; Marchal F; Pocard M; Pezet D; Rullier A; Vendrely V; Denost Q; Asselineau J; Doussau A
Lancet; 2017 Jul; 390(10093):469-479. PubMed ID: 28601342
[TBL] [Abstract][Full Text] [Related]
30. Outcomes of Patients With Local Regrowth After Nonoperative Management of Rectal Cancer After Neoadjuvant Chemoradiotherapy.
Cotti GC; Pandini RV; Braghiroli OFM; Nahas CSR; Bustamante-Lopez LA; Marques CFS; Imperiale AR; Ribeiro U; Salvajoli B; Hoff PM; Nahas SC
Dis Colon Rectum; 2022 Mar; 65(3):333-339. PubMed ID: 34775415
[TBL] [Abstract][Full Text] [Related]
31. The safety and efficacy of total mesorectal excision (TME) surgery following dose-escalation: Surgical outcomes from the organ preservation in early rectal adenocarcinoma (OPERA) trial, a European multicentre phase 3 randomised trial (NCT02505750).
Sun Myint A; Rao C; Barbet N; Thamphya B; Pace-Loscos T; Schiappa R; Magné N; Martel-Lafay I; Mineur L; Deberne M; Zilli T; Dhadda A; Gerard JP
Colorectal Dis; 2023 Nov; 25(11):2160-2169. PubMed ID: 37837240
[TBL] [Abstract][Full Text] [Related]
32. The watch-and-wait strategy versus surgical resection for rectal cancer patients with a clinical complete response after neoadjuvant chemoradiotherapy.
Wang QX; Zhang R; Xiao WW; Zhang S; Wei MB; Li YH; Chang H; Xie WH; Li LR; Ding PR; Chen G; Zeng ZF; Wang WH; Wan XB; Gao YH
Radiat Oncol; 2021 Jan; 16(1):16. PubMed ID: 33468176
[TBL] [Abstract][Full Text] [Related]
33. [Rational evaluation of the complete response after neoadjuvant therapy in locally advanced mid-low rectal cancer: the pros and cons of "watch and wait" strategy].
Gu J
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jun; 22(6):507-513. PubMed ID: 31238630
[TBL] [Abstract][Full Text] [Related]
34. [Application of short-course radiotherapy with total neoadjuvant therapy in the treatment of middle and low rectal cancer].
Chen CJ; Yang CK; Jian JL; Guan S; Xie MM
Zhonghua Yi Xue Za Zhi; 2023 Jan; 103(4):271-277. PubMed ID: 36660788
[No Abstract] [Full Text] [Related]
35. The impact of total neo-adjuvant treatment on nonoperative management in patients with locally advanced rectal cancer: The evaluation of 66 cases.
Asoglu O; Tokmak H; Bakir B; Demir G; Ozyar E; Atalar B; Goksel S; Koza B; Guven Mert A; Demir A; Guven K
Eur J Surg Oncol; 2020 Mar; 46(3):402-409. PubMed ID: 31955995
[TBL] [Abstract][Full Text] [Related]
36. Planned organ preservation for early T2-3 rectal adenocarcinoma: A French, multicentre study.
Gérard JP; Barbet N; Gal J; Dejean C; Evesque L; Doyen J; Coquard R; Gugenheim J; Benizri E; Schiappa R; Baudin G; Benezery K; François E
Eur J Cancer; 2019 Feb; 108():1-16. PubMed ID: 30580125
[TBL] [Abstract][Full Text] [Related]
37. Total neoadjuvant treatment to increase the clinical complete response rate for distal locally advanced rectal cancer (TESS): A study protocol of a prospective, open-label, multicenter, single-arm, phase 2 trial.
Liu S; Wang X; Zhuang Y; Bai S; Wu X; Ye Y; Luo H; Yu H; Wang Q; Chang H; Zeng Z; Cai P; Pan Z; Gao Y; Chen G; Xiao W
Cancer Med; 2023 Jun; 12(12):13352-13360. PubMed ID: 37156624
[TBL] [Abstract][Full Text] [Related]
38. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
[No Abstract] [Full Text] [Related]
39. Efficacy and safety of wait and see strategy versus radical surgery and local excision for rectal cancer with cCR response after neoadjuvant chemoradiotherapy: a meta-analysis.
Zhao GH; Deng L; Ye DM; Wang WH; Yan Y; Yu T
World J Surg Oncol; 2020 Aug; 18(1):232. PubMed ID: 32862826
[TBL] [Abstract][Full Text] [Related]
40. Short-term outcomes of chemoradiotherapy and local excision versus total mesorectal excision in T2-T3ab,N0,M0 rectal cancer: a multicentre randomised, controlled, phase III trial (the TAU-TEM study).
Serra-Aracil X; Pericay C; Badia-Closa J; Golda T; Biondo S; Hernández P; Targarona E; Borda-Arrizabalaga N; Reina A; Delgado S; Vallribera F; Caro A; Gallego-Plazas J; Pascual M; Álvarez-Laso C; Guadalajara-Labajo HG; Mora-Lopez L
Ann Oncol; 2023 Jan; 34(1):78-90. PubMed ID: 36220461
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
